NASDAQ OMX

Arbitrade Ltd. To Establish its World Headquarters in Bermuda

Dela

NEW YORK, June 07, 2018 (GLOBE NEWSWIRE) -- Mr. Leonard Schutzman, Chairman and Chief Executive Officer of Arbitrade, a leading coin and cryptocurrency exchange, said today that its home domicile will be Bermuda. In making the announcement, Chairman Schutzman said the process to winning incorporation started late last year when company representatives first met with Premier David Burt, Minister Wayne Caines, the Minister of National Security who is spearheading the introduction of crypto and digital asset legislation in Bermuda, Minister Wayne Furbert, The Junior Finance Minister, Stephen P. Gift from the Ministry of Finance, representatives from the Bermuda Monetary Authority and Bermuda Business Development Agency. "The company made numerous visits over several months and a considerable amount of work was done to securing our incorporation. Bermuda is justly regarded as the gold standard in the Fintech and Reinsurance industries globally and Arbitrade's goal was always to domicile its head office in this exacting jurisdiction before registering subsidiaries in other countries around the world," Mr. Schutzman said.

He noted Bermuda was one of the very few jurisdictions leading the way with full legislation affecting ICO's and cryptocurrency laws and Arbitrade welcomed cryptocurrency legislation and associated regulations that form a strong foundation in developing the best strategies to advance its business model into other countries. Arbitrade welcomed the stringent Know Your Client (KYC)/Anti Money Laundering (AML) process with which companies will have to comply before they are able to be licensed to operate as a merchant exchange business.  "It seemed to us the only way our industry will receive global acceptance. With this thoughtful and timely structure of Bermuda's laws to guide and support us, Arbitrade can now move forward into over 12 additional countries quickly and then continue to introduce our platforms to more jurisdictions," he said.

Bermuda expects its ICO legislation to be passed within the next three weeks and Arbitrade intends to hold the very first, fully legal, ICO in Bermuda when this happens. Information about the legislation is available on the Government of Bermuda's website.

Once Arbitrade has its licenses in hand, the company will proceed first with its eight-week legally approved ICO, followed by the launch of the Arbitrade platform in late August/early September.

Bermuda is a well-regulated Country Led by the Bermuda Monetary Authority. All new companies are scrutinized to ensure that the jurisdiction is protected and know its customer, hence a sometimes lengthy period of due diligence.

While many countries still wrestle with ways to regulate digital assets businesses, the Bermuda government has passed the Digital Assets Business Act. "This thoughtful and timely action demonstrates, once again, why Bermuda is a world leader in regulating financially related services. The progressive legislation sets the highest standards for those companies who have chosen to establish Digital Assets businesses on the island and validates the company's decision to incorporate and domicile our global headquarters in Bermuda."

Mr. Schutzman said, Arbitrade's management would like to thank everyone for their patience and understanding while it worked to achieve this incredible accomplishment. "This is only the beginning, and the road ahead is going to be extremely busy as management sets up the operating infrastructure of the company, with our head office in Bermuda."

Arbitrade has been locking down all deals regarding our bullion purchases as we move forward with this news. We needed two things to be able to close the bullion negotiations:

1. Be a registered company in Bermuda, and

2. Be a legally licensed and insured company in Bermuda.

"We have already accomplished the first requirement and, we have been advised, the second requirement will happen later this month," Mr. Schutzman said, noting that the company seeks to finish all agreements and deals with all partnering companies before the end of the month. Once this is achieved, it will announce the official ICO dates, the bullion related news, partners information, and the official launch date of Arbitrade. Arbitrade's management and consultants were hoping for earlier dates to receive approvals however this is a long process that has to pass through many channels of Government. We have made it through the most difficult part of the process."

ARBITRADE, through its proprietary software and strategic partnerships, plans to be in all segments of the cryptocurrency business, including currency mining, trading (The ARBITRADE Exchange) gift cards, debit cards, money transfer and Point of Sale processing.

Media Contact:
Victor Webb
Marston Webb International
T: (212) 684-6601, C: (917) 887-0418
e-mail: marwebint@cs.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Arbitrade via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30Pressmeddelande

LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma

Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15Pressmeddelande

BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio

Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05Pressmeddelande

WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public

Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00Pressmeddelande

OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to

Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29Pressmeddelande

ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern

Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum